Daiichi Sankyo

-4.06%

and its operations
Daiichi Sankyo is a global pharmaceutical company based in Japan. It was founded in 2005 through the merger of two Japanese pharmaceutical companies, Daiichi Pharmaceutical and Sankyo Co., Ltd. The company's global headquarters is located in Tokyo, Japan, and it has several research and development sites in Japan, Germany, and the United States.
Daiichi Sankyo is primarily focused on the development of innovative medicines for the treatment of cardiovascular, metabolic, and infectious diseases, as well as oncology. The company also has a strong presence in the over-the-counter and generic drug markets.
Daiichi Sankyo operates in more than 20 countries worldwide and has a diverse portfolio of drugs marketed in over 60 countries. The company's global sales in the fiscal year 2020 were approximately 950 billion yen (about $8.8 billion USD).
In addition to developing and marketing drugs, Daiichi Sankyo is also actively engaged in research and development collaborations with academic institutions and other pharmaceutical companies. The company's goal is to continue expanding its portfolio and delivering innovative treatment options to patients around the world.
Some of Daiichi Sankyo's notable drugs include:
- LIXIANA (rivaroxaban), an oral anticoagulant used to prevent and treat blood clots
- Thromboreductin (tenecteplase), a clot-dissolving enzyme used to treat heart attacks
- EVISTA (raloxifene), a selective estrogen receptor modulator used to treat osteoporosis and reduce the risk of developing breast cancer
- RECLAST (zoledronic acid), an intravenous medication used to treat osteoporosis and prevent bone fractures
- Benicar (olmesartan medoxomil), a blood pressure medication used to treat hypertension
- Oncology drugs, including ENHERTU (trastuzumab deruxtecan), for the treatment of HER2-positive breast and gastric cancer, and pexidartinib, for the treatment of certain types of tumors.

1. Pioneering Pharmaceutical Company: Daiichi Sankyo is a global pharmaceutical company that has been in operation for over 100 years. It has a strong track record of developing innovative medicines and treatments for various diseases and conditions.
2. Global Presence: The company has a strong international presence, with operations in more than 50 countries worldwide. It has a wide network of research, development, and manufacturing facilities in Asia, Europe, and North America.
3. Focused on Key Therapeutic Areas: Daiichi Sankyo is focused on developing treatments in a few key therapeutic areas, namely cardiovascular disease, oncology, pain management, and immune disorders. This allows the company to concentrate its resources and expertise on developing effective treatments in these areas.
4. Commitment to Research and Development: The company invests a significant portion of its revenue into research and development, with a strong focus on developing innovative treatments. This commitment to R&D has helped them to bring many life-saving and life-enhancing medicines to patients worldwide.
5. Collaborative Approach: Daiichi Sankyo embraces a collaborative approach to research and development, partnering with other companies, research institutions, and academic centers to bring its medicines to market. This collaboration helps to accelerate the development of new drugs and treatments.
6. Strong Pipeline: The company has a robust pipeline of innovative medicines in various stages of development, providing a strong foundation for future growth and expansion.
7. Corporate Social Responsibility: Daiichi Sankyo is committed to corporate social responsibility and sustainability, with a focus on ethical business practices, employee well-being, and social and environmental initiatives.
8. Patient-Centered Approach: The company's mission is to strive for the "creation of new healthcare frontiers" through the development of innovative medicines that meet the needs and improve the quality of life of patients worldwide.
9. Diversified Portfolio: In addition to its pharmaceutical business, Daiichi Sankyo also has a presence in other healthcare sectors, including over-the-counter medications, medical devices, and diagnostics, providing a diversified portfolio of products and services.
10. Strong Management Team: The company has a strong and experienced management team with a proven track record of success in the pharmaceutical industry, ensuring the company's strong performance and long-term sustainability.

Daiichi Sankyo is a global pharmaceutical company that focuses on the research, development, and manufacture of innovative medicines. Their business model revolves around developing and commercializing new and improved treatments to address unmet medical needs.
The company's core business strategy is built on three key pillars:
1. Innovation: Daiichi Sankyo invests heavily in research and development (R&D) to discover and develop new medicines across a range of therapeutic areas, including cardiovascular, oncology, and rare diseases. The company has a large global R&D network, including partnerships and collaborations with leading universities and research institutions.
2. Growth: The company’s growth strategy is centered on expanding its global presence and portfolio through strategic partnerships, alliances, and acquisitions. This allows Daiichi Sankyo to access new markets, technologies, and therapies, as well as diversify its product offerings.
3. Responsibility: Daiichi Sankyo has a strong commitment to ethical and socially responsible business practices. This includes conducting all business activities with integrity and transparency, as well as supporting initiatives to improve access to healthcare and address global health challenges.
Overall, Daiichi Sankyo's business model focuses on continually investing in R&D and strategic growth opportunities to drive innovation and bring advanced medicines to patients worldwide.

1. Daiichi Sankyo Company, Limited is a global pharmaceutical company with its headquarters located in Tokyo, Japan. It was founded in 2005 through the merger of two Japanese pharmaceutical companies, Daiichi Pharmaceutical and Sankyo Co., Ltd.
2. The name Daiichi Sankyo translates to the first three virtues in English, which symbolizes the company’s commitment to good health, innovative ideas, and social consciousness.
3. Daiichi Sankyo has a diverse portfolio of prescription medicines, focusing on areas such as cardiovascular, oncology, and pain management. They are also involved in the development of vaccines and biologics.
4. Daiichi Sankyo has a strong presence in Asia, with over 26% of its sales coming from this region. It also has operations in North America, Europe, and other parts of the world.
5. In 2006, Daiichi Sankyo acquired a majority stake (64%) in Indian generic pharmaceutical company Ranbaxy Laboratories. The acquisition allowed Daiichi Sankyo to expand its reach in emerging markets.
6. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact, such as reducing carbon emissions and promoting green procurement.
7. Daiichi Sankyo has a strong focus on research and development (R&D), with over a quarter of its employees dedicated to this area. They have R&D facilities in Japan, Germany, and the United States, among other countries.
8. In 2013, Daiichi Sankyo received approval for its first antibody-drug conjugate (ADC) product, which combines an antibody and a chemotherapy drug to targeted cancer cells and minimize damage to healthy cells.
9. The company has a strong commitment to philanthropy and has set up the Daiichi Sankyo Foundation of Life Science to support research and education in the life sciences field.
10. As of 2021, Daiichi Sankyo had over 16,000 employees worldwide and generated over $8 billion in revenue. It is ranked among the top 20 pharmaceutical companies globally.
See Company Due Diligence: